Boston Scientific Outlook Trails Views  CHICAGO (Reuters) - Boston Scientific Corp. &lt;A HREF="http://www.investor.reuters.com/FullQuote.aspx?ticker=BSX.N target=/stocks/quickinfo/fullquote"&gt;BSX.N&lt;/A&gt;, whose  Taxus heart device has been involved in a major recall, said on  Wednesday preliminary August sales of the device slowed to \$200  million from \$207 million reported in July, and issued an  outlook that was below Wall Street estimates.